AU2007249762A1 - Identification of CDKI pathway inhibitors - Google Patents

Identification of CDKI pathway inhibitors Download PDF

Info

Publication number
AU2007249762A1
AU2007249762A1 AU2007249762A AU2007249762A AU2007249762A1 AU 2007249762 A1 AU2007249762 A1 AU 2007249762A1 AU 2007249762 A AU2007249762 A AU 2007249762A AU 2007249762 A AU2007249762 A AU 2007249762A AU 2007249762 A1 AU2007249762 A1 AU 2007249762A1
Authority
AU
Australia
Prior art keywords
cdki
compound
hydrogen
cell
arrest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007249762A
Other languages
English (en)
Inventor
Bey-Dih Chang
Igor B. Roninson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senex Biotechnology Inc
Original Assignee
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc filed Critical Senex Biotechnology Inc
Publication of AU2007249762A1 publication Critical patent/AU2007249762A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
AU2007249762A 2006-05-15 2007-05-15 Identification of CDKI pathway inhibitors Abandoned AU2007249762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74721306P 2006-05-15 2006-05-15
US60/747,213 2006-05-15
PCT/US2007/011623 WO2007133773A2 (en) 2006-05-15 2007-05-15 Identification of cdki pathway inhibitors

Publications (1)

Publication Number Publication Date
AU2007249762A1 true AU2007249762A1 (en) 2007-11-22

Family

ID=38694544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249762A Abandoned AU2007249762A1 (en) 2006-05-15 2007-05-15 Identification of CDKI pathway inhibitors

Country Status (6)

Country Link
US (1) US20080033000A1 (enExample)
EP (1) EP2021019A4 (enExample)
JP (1) JP2010505386A (enExample)
AU (1) AU2007249762A1 (enExample)
CA (1) CA2652341A1 (enExample)
WO (1) WO2007133773A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
BR112013033417A2 (pt) 2011-06-29 2016-08-16 Otsuka Pharma Co Ltd compostos terapêuticos e métodos relacionados de uso
CN104363913B (zh) * 2012-02-02 2018-08-21 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CA3081443A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
DK3484474T3 (da) 2016-07-13 2024-06-24 Childrens Medical Ct Corp Phenothiazinforbindelser til behandlingen af ribosomale lidelser og ribosomopatier
CA2994329A1 (en) 2017-06-08 2018-12-08 The Children's Medical Center Corporation Compounds and methods for treatment of diamond blackfan anemia
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
EP4746884A2 (en) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CA2557433C (en) * 2004-02-19 2013-05-14 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
EP1748991A1 (en) * 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
WO2006076470A2 (en) * 2005-01-13 2006-07-20 Senex Biotechnology, Inc. High-content screening for drugs against cancer and age-related diseases

Also Published As

Publication number Publication date
CA2652341A1 (en) 2007-11-22
JP2010505386A (ja) 2010-02-25
WO2007133773A3 (en) 2009-01-22
EP2021019A4 (en) 2009-12-09
EP2021019A2 (en) 2009-02-11
US20080033000A1 (en) 2008-02-07
WO2007133773A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
US20080033000A1 (en) Identification of CDKI pathway inhibitors
US20100190807A1 (en) CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
US20090281129A1 (en) Cdki pathway inhibitors and uses thereof
Roninson Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts
US20200048208A1 (en) TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
Zou et al. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer
Verma et al. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells
Mei et al. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis
Afghani et al. Microtubule actin cross-linking factor 1, a novel target in glioblastoma
Hao et al. MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
US20080200531A1 (en) CDKI pathway inhibitors as inhibitors of tumor cell growth
Faloon et al. A small molecule inhibitor of the MITF molecular pathway
Venkatesh et al. In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation
Li et al. Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Vlčková et al. GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
Hsieh et al. Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation
JP2009077705A (ja) Ｃｄｋ阻害剤によって調節される遺伝子発現を同定及び調節するための試薬及び方法
Yurttas et al. Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity
CA2492772A1 (en) Activated checkpoint therapy and methods of use thereof
Shankar et al. Cyclodipeptide c (orn-pro) conjugate with 4-ethylpiperic acid abrogates cancer cell metastasis through modulating mdm2
WO2016198698A2 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
EP3625248A1 (en) Compositions and methods for diagnosing and treating diseases and disorders associated with mutant kcnj5
Abd Rahman et al. Inhibition of angiogenesis and metastasis in colorectal cancer cell lines through KRAS-associated signaling pathways by 2-methoxy-6-undecyl-1, 4-benzoquinone
JP2017521362A (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application